Drugs / RQ3027
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05907044 | May → Jun 2023 | COVID-19 | Affiliated Hospital of Yunnan University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RQ3027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05907044 ↗ |
| Modality | Messenger RNA (mRNA) | “bivalent mRNA vaccines RQ3027(Alpha/Beta+Omicron XBB.1.5)” NCT05907044 ↗ |